Your browser doesn't support javascript.
loading
Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.
Pérez-Olmeda, Mayte; Saugar, José María; Fernández-García, Aurora; Pérez-Gómez, Beatriz; Pollán, Marina; Avellón, Ana; Pastor-Barriuso, Roberto; Fernández-de Larrea, Nerea; Martín, Mariano; Cruz, Israel; Sanmartín, Jose L; Fedele, Giovanni; Paniagua, Jose León; Muñoz-Montalvo, Juan F; Blanco, Faustino; Yotti, Raquel; Oteo-Iglesias, Jesús.
Afiliação
  • Pérez-Olmeda M; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Saugar JM; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Fernández-García A; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
  • Pérez-Gómez B; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Pollán M; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Avellón A; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
  • Pastor-Barriuso R; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Fernández-de Larrea N; CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Martín M; Deputy Directorate of Information Technologies, Ministry of Health, Madrid, Spain.
  • Cruz I; National School of Public Health, Instituto de Salud Carlos III, Madrid, Spain.
  • Sanmartín JL; Deputy Directorate of Information Technologies, Ministry of Health, Madrid, Spain.
  • Fedele G; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
  • Paniagua JL; Instituto de Salud Carlos III, Madrid, Spain.
  • Muñoz-Montalvo JF; Deputy Directorate of Information Technologies, Ministry of Health, Madrid, Spain.
  • Blanco F; General Secretary of Health, Ministry of Health, Madrid, Spain.
  • Yotti R; Instituto de Salud Carlos III, Madrid, Spain.
  • Oteo-Iglesias J; National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain.. Electronic address: jesus.oteo@iscii
J Clin Virol ; 149: 105130, 2022 04.
Article em En | MEDLINE | ID: mdl-35305377
BACKGROUND: The main aims of this study were to analyze trends of SARS-CoV-2 anti-nucleocapsid IgG throughout the four rounds of the seroepidemiologic study ENE-COVID, and compare the fourth-round results of two immunoassays detecting anti-nucleocapsid and anti-RBD IgG. METHODS: ENE-COVID was developed in 2020 (two phases). Phase one included three rounds carried out in April 27-May 11, May 18-June 1, and June 8-June 22. Phase two included a fourth round in the same cohort (November 16-29). A chemiluminescent microparticle immunoassay was offered to participants in the first three rounds (Abbott; anti-nucleocapsid IgG). In the fourth round, we offered this test and a chemiluminescence immunoassay (Beckman; anti-RBD IgG) to i) a randomly selected sub-cohort, ii) participants who were IgG-positive in any of the three first rounds; and iii) participants who were IgG-positive in the fourth round by point-of-care immunochromatography. RESULTS: 10,153 individuals (82.2% of people invited) participated in the fourth round. Of them, 2595 (35.1% of participants with results in the four rounds) were positive for anti-nucleocapsid IgG in at least one round. Anti-nucleocapsid IgG became undetectable in 43.3% of participants with positive first-round results. In fourth round, anti-nucleocapsid and anti-RBD IgG were detected in 5.5% (321/5827) and 5.4% (315/5827) participants of the randomly selected sub-cohort, and in 26.6% (867/3261) and 25.9% (846/3261) participants with at least one previous positive result, respectively. CONCLUSIONS: The IgG response is heterogeneous and conditioned by infection severity. A proportion of SARS-CoV-2 infected population may have negative serologic results in the post-infection months.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Clin Virol Assunto da revista: VIROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Clin Virol Assunto da revista: VIROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha